For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the same...

Thomas, McNerney & Partners raised $216 million for its first fund, which will invest in companies of all stages in medical device, biotech and pharmaceutical sectors. The fund also will seek later-stage spinout opportunities. The...

With three Phase III setbacks, a high profile Phase II setback and more ImClone woes hitting the tape last week, Street watchers hope the industry is simply getting its blowups out of its system early....

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...

(ZymoGenetics spun out, B5; financing, B17) ZymoGenetics Inc., Seattle, Wash. Business: Drug discovery Appointed: Jonathan Leff, managing director at E.M. Warburg, Pincus & Co. LLC; David Hirsh, Robert Wood Johnson professor and chairman of biochemistry...

Novo Nordisk (NVO) subsidiary ZymoGenetics (Seattle, Wash) raised $150 million in a private round. The move establishes ZymoGenetics , which NVO acquired in 1988, as an independent company. ZymoGenetics had operated as NVO's primary U.S. drug...

(Lawsuit, B7; Management, B9) Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy, Hematology, Metabolic Appointed: Jonathan Leff, managing director of E.M. Warburg, Pincus & Co. LLC WIR Staff Hematology...

Sunesis (Redwood City, Calif.), which is developing small molecule therapeutics against protein-protein interactions or enzymes, raised $60 million in a private financing. Investors included CSFB Private Equity; International Biotechnology Trust; Lombard Odier; E.M. Warburg, Pincus;...

It has been a long road for Angiomax bivalirudin, a direct thrombin inhibitor derived from the leech compound hirudin. Biogen Inc. stopped development of the compound, then called Hirulog , in 1994 after a Phase III...